Navigation Links
Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
Date:3/15/2013

itemprop="name">Roger M. Lyons , MD; et al.  Available online at Blood (ASH 54th Annual Meeting Abstracts) 2012 120: Abstract 4394. This abstract reports the preliminary results of a clinical trial of Telintra for the treatment of patients with idiopathic chronic neutropenia (ICN),  a rare group of blood disorders characterized by low circulating white cells, recurrent fevers, inflammation and serious infections.  Telintra treatment of ICN patients with very low white blood cell levels who were not responsive to G‑CSF led to clinically significant reductions in serious infections.  Telintra is the first targeted GSTP1-1 inhibitor that has been shown to have a positive effect on white blood cell levels in ICN and may provide molecular insight into the pathophysiology of ICN.

In 2013, Telik is focusing on: (1) planning and initiating a Phase 3 placebo-controlled randomized registration trial of TELINTRA for the treatment of Low to Intermediate-1 risk MDS and (2) advancing its leading preclinical oncology drug candidate.  In order to initiate the registration trial, we need to secure funding through the establishment of a corporate partnership and licensing agreement, funding from a non- profit agency, or other financing sources.

Financial Outlook

For the full year 2013, Telik anticipates total operating costs and expenses to be in the range of $5.5 million to $6.0 million, which includes non-cash stock-based compensation expense of approximately $0.3 million. The costs for a Phase 3 TELINTRA registration trial are not included in this outlook and would require additional funding. The company's cash utilization for the full year 2013, without any Phase 3 costs, is expected to be in the range of $7.0 million to $7.5 million. The company was able to raise approximately $3.6 million through its At Market Issuance Sales Agreement in the first two months of 2013, and its current existing cash resour
'/>"/>

SOURCE Telik, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Telik Announces Third Quarter 2012 Financial Results
2. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
3. ULURU Inc. Announces Closing Of $440,000 Private Placement
4. Cardica Announces Proposed Public Offering of Common Stock
5. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
7. Simbionix Announces License Agreement for Surgical Videos
8. BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND
9. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
10. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
11. PDI, Inc. Announces $17 Million Multi-Year Sales Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- QT Vascular Ltd., together with its subsidiaries ("QT Vascular" ... design, assembly and distribution of advanced therapeutic solutions for ... into an agreement with a group of investors (the ... This funding will strengthen the Group,s working capital which ... Dr. Eitan Konstantino , Ph.D., ...
(Date:7/27/2015)... York , July 27, 2015 ... Research "Bionics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 7.96 billion in 2014, growing at a ... USD 20.49 billion in 2021. The global bionics ... number of accidents, which is leading to paralysis or amputation ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... Solaris therapeutic modality products. This approval allows the company to sell ... countries around the world. "Receiving the CE Mark represents ... stated Kelvyn H. Cullimore Jr. , president and CEO of ... network into China , Japan ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:7/27/2015)... Dallas, TX (PRWEB) , ... July 27, 2015 , ... ... remainder of 2015. , The center invites all those prospective joint-replacement patients, along ... Monday and Thursday of each month, with Monday classes (Aug 6, Sept 8 [Tue ...
(Date:7/27/2015)... ... 27, 2015 , ... Send Word Now, the ... collaboration, announced today the latest software release for its award-winning alerting service, ... , This software release gives the widely used online application a fresh look ...
(Date:7/27/2015)... Houston, TX (PRWEB) , ... July 27, 2015 , ... ... million in actual and punitive damages against Canadian stock promoter Robert Kubbernus based on ... down by a twelve-person jury and accepted by the court in Cause No. 2010-09675; ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing program of ... its options. Already an industry leader because of its use of iPad technology ... latest successful trends in helping people to overcome addiction and live healthy, productive ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... ... entitled "Applying Data To Reduce Hospital Readmissions." , The Centers for Medicare and ... facility-level data used as part of their penalty calculation. Known as the QualityNet ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2
... Canadian Cancer Society has recommended that citizens of all ages should ... and that elderly people// should take Vitamin D supplements. ... 'Oh good, I can stay out in the sun all day,' ... little sun goes a long way. You don't need to get ...
... month study conducted by the rheumotologists in the University ... in the form of Adkins-type diet for weight loss, ... contrary to the earlier findings conducted in animal studies. ... the online issue of the journal Osteoporosis International. Low ...
... doctors here sucessfully removed a 'minute spring' which had got ... // ,Dr Palaniappan of Apollo Hospital here, who ... told PTI here that Muniraj was suffering from a wheezing ... one-and-a-half months., ,After trying different treatments, the boy's father ...
... human-to-human transmission of the deadly bird flu virus among members ... agency has sought to assure the public that potentially dangerous ... however maintained that human contagion cannot be ruled out in ... ,So far there has been no evidence that efficient human-to-human ...
... has been announced states that all the state schools are to ... This is part of their drive against obesity. , ... milk to pupils aged 3 to 18. The ruling also applies ... and to cartons sold in vending machines. ,This ban ...
... today took out a rally here to oppose the ... OBC in higher educational institutions. // ... and engineering colleges today took out a rally and ... and other important places of the city to convey ...
Cached Medicine News:Health News:Good News For The Obese People 2Health News:All State Run Schools Are To Ban Whole Milk To Children 2Health News:All State Run Schools Are To Ban Whole Milk To Children 3
... Richmond Products includes the four demonstration plates, the ... for a total of 24 plates. Each of ... and clean page selection. The test also includes ... laminated copy of the score sheet. The score ...
... charts are recognized internationally as a ... deficiency. With normal color perception, the ... visible. Each color test plate in ... printed to measure incrementally higher color ...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Medicine Products: